Janssen seeks expanded approval for DARZALEX in treating AL amyloidosis
Janssen Pharmaceutical Companies of Johnson & Johnson has recently submitted a Type II variation application to the European…
Memo Therapeutics secures $15.5m in Series B to propel antibody development for COVID-19 and BK virus treatment
Memo Therapeutics, a Swiss biotech company, has successfully raised CHF 14 million (approximately $15.56 million) in a Series…
Pfizer’s Phase 3 clinical trial of XELJANZ in ankylosing spondylitis: A breakthrough in treatment
Pfizer has announced the successful completion of a Phase 3 clinical trial for its drug XELJANZ (tofacitinib) in…
Bristol Myers Squibb’s Opdivo and Yervoy combination approved for metastatic NSCLC in Europe
Bristol Myers Squibb (BMS) has announced a major breakthrough in cancer treatment with the European Commission’s (EC) approval…
Humanigen announces positive interim results for lenzilumab in COVID-19 phase 3 trial
Humanigen, a U.S.-based biopharmaceutical company, has revealed promising interim data from its phase 3 clinical trial of lenzilumab,…
BRILINTA FDA approval: A major step in reducing stroke risks in acute ischemic stroke and high-risk TIA patients
AstraZeneca has secured U.S. Food and Drug Administration (FDA) approval for BRILINTA (ticagrelor), expanding its use to reduce…
Seres Therapeutics begins Phase 1b trial for SER-301 in active ulcerative colitis
Seres Therapeutics, a prominent US-based biotech company, has announced the commencement of dosing in a Phase 1b clinical…
Novo Nordisk’s $1.8bn acquisition of Emisphere Technologies: What it means for the future of oral biologics
Danish pharmaceutical giant Novo Nordisk has reached a significant milestone in the development of oral biologic therapies, agreeing…
PerkinElmer acquisition of Horizon Discovery Group: A strategic move to enhance genomic and cell engineering capabilities
PerkinElmer, a leading US-based provider of life sciences and diagnostics solutions, has announced its acquisition of Horizon Discovery…
FTC grants conditional approval for Mylan’s acquisition of Upjohn: What this means for the pharma industry
The U.S. Federal Trade Commission (FTC) has granted conditional approval for Mylan’s acquisition of Upjohn, Pfizer’s off-patent branded…